Long-term outcome of reoperations for medullary thyroid carcinoma

Elizabeth Fialkowski, Mary DeBenedetti, Jeffrey Moley

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Most patients with medullary thyroid carcinoma (MTC) have persistent disease after primary surgery, as evidenced by calcitonin elevation. Previous reports showed that reoperation on selected patients yields immediate calcitonin normalization in one-third of patients. Long-term follow-up data are needed to assess the outcome in such patients. This report aims to provide 8- to 10-year follow-up on reoperations for persistent or recurrent MTC. Methods: An Internal Review Board (IRB) approved database on patients treated for MTC has been prospectively maintained. This database was reviewed to report follow-up data on calcitonin levels and survival. Results: Between 1992 and 2006, 148 patients underwent reoperations for recurrent or persistent MTC (55 patients had 59 reoperations for palliation, and 93 patients had 105 reoperations for cure). Of the 93 patients operated on for cure (44 with hereditary MTC, 49 with the sporadic form), 8-10-year follow-up data were available on 56. Four patients died of disease (4.3% of 93). Two died of unrelated causes, and were excluded from calcitonin outcome analysis. Fourteen patients of 54 (26.0%) have unstimulated calcitonin levels of <10 pg/ml at 8-10 years. Eleven additional patients (20.4%) have levels <100 pg/ml. None of these 25 patients (46.4%) have radiologic recurrence. Conclusions: Previous reports demonstrated the low morbidity of reoperation for MTC in experienced hands, and success was determined by lowering of calcitonin levels. Follow-up data demonstrate that at least one third of such patients have long-term eradication of their disease following reoperation, as evidenced by biochemical and imaging studies.

Original languageEnglish (US)
Pages (from-to)754-765
Number of pages12
JournalWorld Journal of Surgery
Volume32
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Reoperation
Calcitonin
Medullary Thyroid cancer
Databases
Disease Eradication

ASJC Scopus subject areas

  • Surgery

Cite this

Long-term outcome of reoperations for medullary thyroid carcinoma. / Fialkowski, Elizabeth; DeBenedetti, Mary; Moley, Jeffrey.

In: World Journal of Surgery, Vol. 32, No. 5, 05.2008, p. 754-765.

Research output: Contribution to journalArticle

Fialkowski, Elizabeth ; DeBenedetti, Mary ; Moley, Jeffrey. / Long-term outcome of reoperations for medullary thyroid carcinoma. In: World Journal of Surgery. 2008 ; Vol. 32, No. 5. pp. 754-765.
@article{3298b02418754262bc1e6c0c4f5e2853,
title = "Long-term outcome of reoperations for medullary thyroid carcinoma",
abstract = "Background: Most patients with medullary thyroid carcinoma (MTC) have persistent disease after primary surgery, as evidenced by calcitonin elevation. Previous reports showed that reoperation on selected patients yields immediate calcitonin normalization in one-third of patients. Long-term follow-up data are needed to assess the outcome in such patients. This report aims to provide 8- to 10-year follow-up on reoperations for persistent or recurrent MTC. Methods: An Internal Review Board (IRB) approved database on patients treated for MTC has been prospectively maintained. This database was reviewed to report follow-up data on calcitonin levels and survival. Results: Between 1992 and 2006, 148 patients underwent reoperations for recurrent or persistent MTC (55 patients had 59 reoperations for palliation, and 93 patients had 105 reoperations for cure). Of the 93 patients operated on for cure (44 with hereditary MTC, 49 with the sporadic form), 8-10-year follow-up data were available on 56. Four patients died of disease (4.3{\%} of 93). Two died of unrelated causes, and were excluded from calcitonin outcome analysis. Fourteen patients of 54 (26.0{\%}) have unstimulated calcitonin levels of <10 pg/ml at 8-10 years. Eleven additional patients (20.4{\%}) have levels <100 pg/ml. None of these 25 patients (46.4{\%}) have radiologic recurrence. Conclusions: Previous reports demonstrated the low morbidity of reoperation for MTC in experienced hands, and success was determined by lowering of calcitonin levels. Follow-up data demonstrate that at least one third of such patients have long-term eradication of their disease following reoperation, as evidenced by biochemical and imaging studies.",
author = "Elizabeth Fialkowski and Mary DeBenedetti and Jeffrey Moley",
year = "2008",
month = "5",
doi = "10.1007/s00268-007-9317-7",
language = "English (US)",
volume = "32",
pages = "754--765",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Long-term outcome of reoperations for medullary thyroid carcinoma

AU - Fialkowski, Elizabeth

AU - DeBenedetti, Mary

AU - Moley, Jeffrey

PY - 2008/5

Y1 - 2008/5

N2 - Background: Most patients with medullary thyroid carcinoma (MTC) have persistent disease after primary surgery, as evidenced by calcitonin elevation. Previous reports showed that reoperation on selected patients yields immediate calcitonin normalization in one-third of patients. Long-term follow-up data are needed to assess the outcome in such patients. This report aims to provide 8- to 10-year follow-up on reoperations for persistent or recurrent MTC. Methods: An Internal Review Board (IRB) approved database on patients treated for MTC has been prospectively maintained. This database was reviewed to report follow-up data on calcitonin levels and survival. Results: Between 1992 and 2006, 148 patients underwent reoperations for recurrent or persistent MTC (55 patients had 59 reoperations for palliation, and 93 patients had 105 reoperations for cure). Of the 93 patients operated on for cure (44 with hereditary MTC, 49 with the sporadic form), 8-10-year follow-up data were available on 56. Four patients died of disease (4.3% of 93). Two died of unrelated causes, and were excluded from calcitonin outcome analysis. Fourteen patients of 54 (26.0%) have unstimulated calcitonin levels of <10 pg/ml at 8-10 years. Eleven additional patients (20.4%) have levels <100 pg/ml. None of these 25 patients (46.4%) have radiologic recurrence. Conclusions: Previous reports demonstrated the low morbidity of reoperation for MTC in experienced hands, and success was determined by lowering of calcitonin levels. Follow-up data demonstrate that at least one third of such patients have long-term eradication of their disease following reoperation, as evidenced by biochemical and imaging studies.

AB - Background: Most patients with medullary thyroid carcinoma (MTC) have persistent disease after primary surgery, as evidenced by calcitonin elevation. Previous reports showed that reoperation on selected patients yields immediate calcitonin normalization in one-third of patients. Long-term follow-up data are needed to assess the outcome in such patients. This report aims to provide 8- to 10-year follow-up on reoperations for persistent or recurrent MTC. Methods: An Internal Review Board (IRB) approved database on patients treated for MTC has been prospectively maintained. This database was reviewed to report follow-up data on calcitonin levels and survival. Results: Between 1992 and 2006, 148 patients underwent reoperations for recurrent or persistent MTC (55 patients had 59 reoperations for palliation, and 93 patients had 105 reoperations for cure). Of the 93 patients operated on for cure (44 with hereditary MTC, 49 with the sporadic form), 8-10-year follow-up data were available on 56. Four patients died of disease (4.3% of 93). Two died of unrelated causes, and were excluded from calcitonin outcome analysis. Fourteen patients of 54 (26.0%) have unstimulated calcitonin levels of <10 pg/ml at 8-10 years. Eleven additional patients (20.4%) have levels <100 pg/ml. None of these 25 patients (46.4%) have radiologic recurrence. Conclusions: Previous reports demonstrated the low morbidity of reoperation for MTC in experienced hands, and success was determined by lowering of calcitonin levels. Follow-up data demonstrate that at least one third of such patients have long-term eradication of their disease following reoperation, as evidenced by biochemical and imaging studies.

UR - http://www.scopus.com/inward/record.url?scp=42449107686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449107686&partnerID=8YFLogxK

U2 - 10.1007/s00268-007-9317-7

DO - 10.1007/s00268-007-9317-7

M3 - Article

C2 - 18188643

AN - SCOPUS:42449107686

VL - 32

SP - 754

EP - 765

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 5

ER -